Shams Shahemabadi A, Salehi F, Hashemi A, Vakili M, Zare F, Esphandyari N, Kashanian S
Immunology department, Faculty of medicine, Shahid Sadoughi University of Medical Sciences and Health Services.
Central laboratory of Yazd, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Iran J Ped Hematol Oncol. 2012;2(4):133-9. Epub 2012 Sep 22.
There is a decrease in vaccine-specific antibody to certain vaccine-preventable diseases in children after chemotherapy, but the frequency of non-immune patients is not clear. In the present case-control study, was taken under investigation protection level to Hepatitis B infection in children 6 months after completing chemotherapy.
In this study 68 patients with cancer and 68 healthy children were enrolled. Patients were 1.5 -12 years old with completed standard chemotherapy at least for 6 months. All the patients and healthy children were negative for HBsAg and HBeAg and had received Hepatitis B vaccination. IgG antibody concentrations against Hepatitis B Virus (HBV) were determined in the patients receiving chemotrapy and healthy subjects serum by ELISA method. IgG antibody titer > 10 mIU/ml was considered as baseline protective titer for preventing HBV infection.
Anti-HBs antibody titer in 19.12% of patients was less than 10 mIU/ml and 11.76% of the patients had borderline antibody titer (10-20 mIU/ml). In healthy subjects, 2.94% and 5.88% had antibody titer < 10 mIU/ml and 10-20 mIU/ml, respectively. According to statistical analysis, frequency of non immune subjects in children with cancer was significantly higher than those in healthy children (P-value=0.024).
HBV vaccination post-intensive chemotherapy in the children with cancer is strongly recommended.
化疗后儿童对某些疫苗可预防疾病的疫苗特异性抗体减少，但非免疫患者的频率尚不清楚。在本病例对照研究中，对完成化疗6个月后的儿童乙肝感染保护水平进行了调查。
本研究纳入了68例癌症患者和68名健康儿童。患者年龄为1.5至12岁，至少完成标准化疗6个月。所有患者和健康儿童的HBsAg和HBeAg均为阴性，且均接种过乙肝疫苗。采用ELISA法测定接受化疗的患者和健康受试者血清中抗乙肝病毒（HBV）IgG抗体浓度。IgG抗体滴度>10 mIU/ml被认为是预防HBV感染的基线保护滴度。
19.12%的患者抗-HBs抗体滴度低于10 mIU/ml，11.76%的患者抗体滴度处于临界值（10-20 mIU/ml）。在健康受试者中，抗体滴度<10 mIU/ml和10-20 mIU/ml的分别为2.94%和5.88%。根据统计分析，癌症患儿中非免疫受试者的频率显著高于健康儿童（P值=0.024）。
强烈建议对癌症患儿在强化化疗后接种乙肝疫苗。
